TEDA Unveils Plan For Biopharmaceutical Industry
This article was originally published in PharmAsia News
Executive Summary
The Tianjin Economic-Technological Development Area recently unveiled its plans for the biopharmaceutical industry. By 2015, it aims to establish a biopharmaceutical industry worth RMB 50 billion, attracting more than 40 large manufacturing enterprises and targeting export rates of 30 percent. TEDA seeks to be an important Asia-Pacific pharmaceutical R&D and manufacturing hub with links to international contract research and manufacturing organizations. A biopharmaceutical industry cluster will be set up to integrate pharmaceutical MNCs, local leading companies and small- and medium-sized innovative enterprises. TEDA aims to develop its own unique characteristics in the CRO, CMO and medical device domains, nurture a core batch of leading pioneers for Tianjin's biopharmaceutical industry and make breakthroughs in new drug creation. (Click here for more - Chinese Language)
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.